That likely only increases the appetite of biotech investors to bet on the next thing. But keep in mind the deal offers some ...

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...

Stock index futures jump on reports of Senate breakthrough to end shutdown. Taiwan Semi's October revenue rises 17% YoY, ...

The start-up is making antivirals and cancer drugs for Big Pharma—and working to treat reproductive problems on its own ...

During his remarks to military leaders at Marine Corps Base Quantico several weeks ago, Donald Trump ranted about the Gulf of Mexico (or the Gulf of America, according to him). He falsely claimed that ...

Metsera's lead pipeline asset is MET-097i, a GLP-1 receptor agonist designed for once-monthly injection. Novo's weight-loss drugs Wegovy and Eli Lilly's Zepbound and Mounjaro require weekly injections ...

Pfizer and Novo Nordisk are locked in a bidding war for biotech firm Metsera as the pharmaceutical giants seek to augment ...

Novo Nordisk and Pfizer's multibillion-dollar fight over who gets to buy an anti-obesity biotech has morphed into a narrative ...

Viking Global's $45 million investment in Metsera, a biotech company is caught in a bidding war between Pfizer and Novo ...

Dow Jones Top Company Headlines at 11 AM ET: Novo Nordisk and Pfizer Sweeten Their Offers for Weight-Loss Drug Startup Metsera | Pfizer ... Novo Nordisk and Pfizer Sweeten Their Offers for Weight-Loss ...